Linden Capital snaps up Arsenal’s BioIVT

The Chicago firm adds to an already busy year of healthcare dealmaking with an $800m-plus deal for the global provider of biological specimens and value-added services.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this